PMID- 3026238
OWN - NLM
STAT- MEDLINE
DCOM- 19870206
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 6
IP  - 5
DP  - 1986 Sep-Oct
TI  - Ambulatory combination chemotherapy with oral etoposide and cisplatin for 
      advanced non small cell lung carcinoma patients. A phase II study.
PG  - 977-81
AB  - Thirty nine male patients with locally advanced and/or extensive non small cell 
      lung cancer (NSCLC) were treated with oral etoposide (240 mg/m2 days 1 to 3) and 
      cisplatin (100 mg/m2 day 4) according to a fully ambulatory schedule. Eight out 
      of 33 (24%) evaluable patients achieved a partial response (PR) and 6 a minor 
      response (MR). Stable disease (SD) was observed in 7 (25%) and progressive 
      disease (P.D.) in 12 (26%). Median survival time (MST) of all patients was 8 
      months. No difference in MST was observed between limited (LD) and extensive 
      disease (ED) patients. Only overall responding patients (PR + MR + SD) in the 
      E.D. subgroup lived significantly longer than PD patients. Patients with LD did 
      not obtain a significant survival benefit whether or not a response was achieved. 
      The overall toxic cost of the regimen was low and patient tolerance remarkably 
      good. This combination chemotherapy can safely be recommended for ambulatory use 
      and does not seem to compromise heavily the patients' quality of life.
FAU - Focan, C
AU  - Focan C
FAU - Le Hung, S
AU  - Le Hung S
FAU - Frere, M H
AU  - Frere MH
FAU - Schallier, D
AU  - Schallier D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/*administration & dosage/adverse effects/therapeutic use
MH  - Drug Evaluation
MH  - Etoposide/*administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1986 Sep-Oct;6(5):977-81.